The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move reflecting an aggressive growth strategy within the healthcare sector, AbbVie is reportedly nearing a major deal to acquire Apogee Therapeutics. According to reports, the company is in advanced negotiations to purchase the inflammatory disease drug developer for approximately $10.9 billion in an all-cash transaction. The acquisition aims to bolster AbbVie's portfolio of innovative treatments following its strong performance in the first quarter.
This potential deal arrives as biopharmaceutical giants seek to offset revenue declines from legacy drugs, with AbbVie competing against peers like Eli Lilly and Pfizer in the high-growth immunology market. Per market data, the proposed valuation suggests a significant premium for Apogee’s pipeline, mirroring a broader industry trend of multi-billion dollar acquisitions aimed at securing promising clinical assets.
Sign in to access this content
Sign InInvestors are closely watching ABBV shares, which stood at $216.63 at close on June 18, 2026, after trading between a low of $215.37 and a high of $222.30. Looking ahead, market participants will monitor upcoming U.S. retail sales data for broader sentiment, while the primary focus remains on the official confirmation and financing structure of this substantial cash outflow.